Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multicenter clinical phase III study involving about 105
cancer patients aged >18 years who are receiving palliative chemotherapy and who are
suffering from chemotherapy associated anemia. A standard treatment group (ERYPO®) will be
included to provide a reference reflecting current standard medical practice.